Reviva Pharmaceuticals Holdings, Inc. (RVPH)
OTCMKTS · Delayed Price · Currency is USD
0.6122
+0.01895 (3.19%)
At close: Jun 4, 2026
Reviva Pharmaceuticals Holdings Employees
Reviva Pharmaceuticals Holdings had 14 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
14
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,187,718
Market Cap
8.03M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 14 | 0 | - |
| Dec 31, 2024 | 14 | -1 | -6.67% |
| Dec 31, 2023 | 15 | 5 | 50.00% |
| Dec 31, 2022 | 10 | 5 | 100.00% |
| Dec 31, 2021 | 5 | 0 | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Adaptimmune Therapeutics | 506 |
| NKGen Biotech | 26 |
| Brainstorm Cell Therapeutics | 20 |
| AccuStem Sciences | 4 |
| Synlogic | 1 |
Reviva Pharmaceuticals Holdings News
- 17 days ago - Reviva to Participate in Fireside Chat at A.G.P.'s Annual Healthcare Company Showcase - GlobeNewsWire
- 19 days ago - Reviva Pharmaceuticals Holdings Slides: Corporate presentation - Filings
- 22 days ago - Reviva Reports First Quarter 2026 Financial Results and Recent Business Highlights - GlobeNewsWire
- 2 months ago - Reviva Reports Full Year 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 2 months ago - Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering - GlobeNewsWire
- 2 months ago - Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering - GlobeNewsWire
- 5 months ago - Reviva to Present at the Sachs 9th Annual Neuroscience Innovation Forum - GlobeNewsWire
- 5 months ago - Reviva Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia - GlobeNewsWire